Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Summary
Absci priced a $100 million underwritten offering of common stock with participation from strategic and financial investors. The company plans to use the proceeds to advance its ABS-201 program for androgenetic alopecia and endometriosis, along with general corporate purposes. The deal includes major institutions such as Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile. The offering is expected to close on June 25, 2026, subject to customary conditions.
Funding
Amount
$100.0M
Total raised
Date
June 24, 2026
Announcement date
Investors
Redmile Group, Eli Lilly and
Lead investors
Company
absci.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AI Classifications
Labels
No AI classifications detected